ENDRA Life Sciences Inc(NDRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NDRA ENDRA Life Sciences Inc

Trading 05-01 11:55:07 EDT

4.85

-0.02

-0.41%

High5.39	Low4.85	Vol4.40K
Open4.99	D1 Closing4.87	Amplitude11.09%
Mkt Cap6.02M	Tradable Cap5.67M	Total Shares1.24M
T/O22.08K	T/O Rate0.38%	Tradable Shares1.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NDRA","market":"US","secType":"STK","nameCN":"ENDRA Life Sciences Inc","latestPrice":4.8501,"timestamp":1777650902747,"preClose":4.87,"halted":0,"volume":4404,"delay":0,"changeRate":-0.004086242299794622,"floatShares":1169800,"shares":1240751,"eps":-8.93,"marketStatus":"Trading","change":-0.0199,"latestTime":"05-01 11:55:07 EDT","open":4.99,"high":5.39,"low":4.8501,"amount":22083.0269652,"amplitude":0.110862,"askPrice":5,"askSize":12,"bidPrice":4.84,"bidSize":24,"shortable":3,"etf":0,"ttmEps":-8.93,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777665600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.87,"postHourTrading":{"tag":"盘后","latestPrice":4.87,"preClose":4.87,"latestTime":"19:05 EDT","volume":28,"amount":135.88,"timestamp":1777590316662,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.274331},"requestUrl":"/m/hq/s/NDRA/tweets","defaultTab":"tweets","newsList":[{"id":"2629036172","title":"ENDRA risks Nasdaq delisting after falling below $2.5 million equity requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629036172","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629036172?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:01","pubTimestamp":1776772909,"startTime":"0","endTime":"0","summary":"Nasdaq warned ENDRA Life Sciences on April 20, 2026 that it is out of compliance with Listing Rule 5550 after reporting stockholders’ equity of 2,260,120 in its 2025 Form 10-K.Staff letter said ENDRA faces delisting unless it requests a hearing before Nasdaq Hearings Panel.ENDRA plans to request hearing, which would stay delisting action pending panel decision.Company is evaluating steps to regain minimum 2,500,000 stockholders’ equity requirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL2z3BL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551895","title":"ENDRA Life Sciences Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551895","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551895?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:55","pubTimestamp":1774997718,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc reports results for the quarter ended September 30 - Earnings SummaryENDRA Life Sciences Inc NDRA.OQ reported a quarterly adjusted loss of $2.10 per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J2KY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624553765","title":"ENDRA Life Sciences Q4 EPS $(3.25) Misses $(1.95) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624553765","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624553765?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:22","pubTimestamp":1774992172,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(3.25) per share which missed the analyst consensus estimate of $(1.95) by 66.67 percent. This is a 55.78 percent increase over losses of $(7.35) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51586945/endra-life-sciences-q4-eps-3-25-misses-1-95-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ENDRA Life Sciences Q4 EPS $(3.25) Misses $(1.95) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624663530","title":"ENDRA Life Sciences Q4 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2624663530","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624663530?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:29","pubTimestamp":1774988984,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Q4 net loss narrowsOverviewUS thermoacoustic imaging firm's Q4 operating expenses fell, narrowing net loss yr/yrCompany initiated review of strategic alternatives to maximize share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL1N40J179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537904","title":"ENDRA FY25 net loss narrows to $7 million; operating expenses fall to $5.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537904","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537904?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:08","pubTimestamp":1774987682,"startTime":"0","endTime":"0","summary":"ENDRA reported a net loss of $7.0 million for fiscal 2025, narrowing from $11.5 million.Operating expenses fell to $5.8 million from $10.8 million, due to streamlining actions taken throughout 2024.Cash and cash equivalents ended 2025 at $762,365; digital assets totaled $2.0 million.Board initiated a process on March 25, 2026 to evaluate strategic alternatives to maximize shareholder value.CEO Alexander Tokman said ENDRA strengthened clinical evidence for TAEUS Liver and remains confident in the technology’s long-term potential while continuing to execute during the review process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via Business Wire  o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbXd3Zs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537674","title":"Press Release: ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537674","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537674?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:05","pubTimestamp":1774987500,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc.  , a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease , today reported financial results for the quarter and year ended December 31, 2025, and provided a business update.--  On March 25, 2026, the Company announced that its Board of. Directors has initiated a process to evaluate strategic. --  The Company intends to continue executing on its strategic and. operating initiatives during the review process, and has not set a. --  On November 20, 2025, ENDRA announced positive results from its. feasibility study that demonstrated the ability of TAEUS Liver, as. redesigned in 2025, to accurately quantify liver fat fraction -- a. key MASLD/MASH biomarker -- with a Pearson correlation coefficient. concordance with MRI-PDFF, the industry's gold standard for. thresholds of 12-17% and 20-22%, thereby positioning the device as. a clinical SLD tool for future use in pharmaceutical trials.for long-term monitoring of S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","NDRA","BK4022","BK4082","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622875801","title":"ENDRA Life Sciences Inc  expected to post a loss of $1.23 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622875801","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622875801?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:17","pubTimestamp":1774624666,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc  expected to post a loss of $1.23 a share - Earnings Preview ENDRA Life Sciences Inc NDRA.OQ NDRA.O is expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F1GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622079776","title":"ENDRA Life Sciences Inc - on March 19 ,Reduced Number of Employees in Order to Reduce Cash Expenditures and Extend Its Operational Runway- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622079776","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622079776?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:25","pubTimestamp":1774445115,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622079459","title":"BRIEF-Endra Life Sciences Initiates Review Of Strategic Alternatives To Maximize Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2622079459","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622079459?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:18","pubTimestamp":1774444711,"startTime":"0","endTime":"0","summary":"BRIEF-Endra Life Sciences Initiates Review Of Strategic Alternatives To Maximize Shareholder ValueENDRA Life Sciences Inc NDRA.O:ENDRA LIFE SCIENCES INITIATES REVIEW OF STRATEGIC ALTERNATIVES TO MAXIM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUANWPMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622407316","title":"ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2622407316","media":"Reuters","labels":["merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622407316?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:06","pubTimestamp":1774440371,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales. The Board of Directors initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.Options under review include strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or a sale or merger of the company.Lucid Capital Management was engaged as financial advisor, and K&L Gates was engaged as legal counsel for the review process.Chief Executive Officer Alexander Tokman said the review is intended to assess available options and determine the most appropriate path forward for the company and its shareholders.Management plans to continue executing strategic and operating initiatives while the review is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLZgyT1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622073600","title":"ENDRA Life Sciences Inc: Continue to Execute on Its Strategic and Operating Initiatives During Review Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073600?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUANWPMW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622073582","title":"ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073582","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073582?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUANWPMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NDRA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622073578","title":"ENDRA Life Sciences Inc - Board to Evaluate Strategic Investments, Mergers, Asset Sales, or Sale of Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073578?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUANWPMW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622707871","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2622707871","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622707871?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:55","pubTimestamp":1774439700,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nAQN2LRNWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614023862","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:39 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2614023862","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614023862?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:39","pubTimestamp":1772116759,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:39 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nAQN2LNX6G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614898044","title":"ENDRA TAEUS Liver Device Shows MRI-Level Consistency in Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2614898044","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614898044?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:00","pubTimestamp":1772110847,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. reported results from a clinical study assessing measurement consistency of its TAEUS Liver device for quantifying liver fat in steatotic liver disease. The study included 14 subjects and 56 measurements performed by independent operators, and reported an intraclass correlation coefficient of 0.89 and a standard error of measurement of 3.3%. The company stated that the results have already been reported in the announcement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL5G8hnp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589311923","title":"ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589311923","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589311923?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:25","pubTimestamp":1765189500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NDRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 05:25 ET (10:25 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588884239","title":"ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884239","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884239?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:01","pubTimestamp":1764853263,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. has announced new results from a recently completed feasibility study of its TAEUS Liver device, designed for the early detection and monitoring of steatotic liver disease . The study, which included 40 subjects with a BMI range of 21 to 47, demonstrated that the TAEUS thermo-acoustic fat fraction  measurement closely matches the performance of MRI-PDFF, the current gold standard, at key liver fat fraction  thresholds of 12-17% and 20-22%. These thresholds are significant for clinical therapy decisions and clinical trial enrollment. The device achieved an average positive predictive value  of 100% and accuracy of 95% in the 12-17% LFF range, and a PPV of 90% and accuracy of 94% in the 20-22% range. ENDRA is conducting a second feasibility study in London, Ontario, Canada, expected to be completed in the coming months, and plans to engage with the FDA in 2026 regarding a pivotal study to support a De Novo submission.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9WpQd9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588840458","title":"ENDRA Life Sciences Inc - Second Feasibility Study for Taeus Liver Device Begun in London, Ontario","url":"https://stock-news.laohu8.com/highlight/detail?id=2588840458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588840458?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABXN0BH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NDRA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588088492","title":"ENDRA’s Taeus® Liver Matches Mri-Pdff Performance at Key Clinical Thresholds, Positioning Device for Masld/Mash Trial Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588088492?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABXN0BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.endrainc.com","stockEarnings":[{"period":"1week","weight":-0.026},{"period":"1month","weight":0.0473},{"period":"3month","weight":0.2816},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.1897},{"period":"ytd","weight":0.0751}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.052625},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.058832},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.150883},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.084253},{"month":5,"riseRate":0.125,"avgChangeRate":-0.13671},{"month":6,"riseRate":0.75,"avgChangeRate":0.032519},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.005394},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.12196},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.06489},{"month":10,"riseRate":0.222222,"avgChangeRate":0.02267},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.075145},{"month":12,"riseRate":0.555556,"avgChangeRate":0.176663}],"exchange":"NASDAQ","name":"ENDRA Life Sciences Inc","nameEN":"ENDRA Life Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENDRA Life Sciences Inc(NDRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENDRA Life Sciences Inc(NDRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENDRA Life Sciences Inc,NDRA,ENDRA Life Sciences Inc股票,ENDRA Life Sciences Inc股票老虎,ENDRA Life Sciences Inc股票老虎国际,ENDRA Life Sciences Inc行情,ENDRA Life Sciences Inc股票行情,ENDRA Life Sciences Inc股价,ENDRA Life Sciences Inc股市,ENDRA Life Sciences Inc股票价格,ENDRA Life Sciences Inc股票交易,ENDRA Life Sciences Inc股票购买,ENDRA Life Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENDRA Life Sciences Inc(NDRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENDRA Life Sciences Inc(NDRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction